Company / SG&A Expense
Zenas BioPharma, Inc. SG&A Expense History
FY2023-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$53.3M
FY2025
5-year range
$17.1M / $53.3M
FY2023-FY2025
Trend
+211.6%
vs FY2024
Sector context
#154 of 213
Health Care
What the data says
SG&A Expense changed +212% YoY in FY2025, a notable deviation from the 2-year average annual change of +106%.
Based on SEC 10-K filings.
$53M in FY2025.
Increased from $17M to $53M over the past 2 years.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#60 of 213 in Health CareTop 28% of 213This company $53.3M Sector average $722.3M
▼
-92.6% below sector average
Key checks
Key Insights
- In FY2025, sg&a expense increased 211.6% year-over-year.
- Ranks #154 out of 213 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -3.51 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $53.3M | +211.6% |
| FY2024 | $17.1M | +0.0% |
| FY2023 | $17.1M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026